Myriad announces agreement with Sanofi to measure predictive cardiovascular biomarkers
Myriad announced it will work with Sanofi to perform a biomarker analysis of blood samples from the Evaluation of Lixisenatide in Acute Coronary Syndrome trial (NCT01147250). Sanofi will provide approximately 5,300 serum samples from the ELIXA trial. Financial terms of the deal were not disclosed. October 25, 2016